Goldman Sachs Starts Sagimet at Sell, Sees 35% Downside Into AURORA The bank says AURORA endpoints and teen compliance may not match China’s Phase 3 results. Credit: Sagimet Biosciences Subscribe now Already have an account? Sign in.
